Veritas In Silico Inc. (JP:130A) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veritas In Silico Inc. has revised its financial forecast for FY2024, anticipating a significant drop in revenue and profits due to delays in securing two new contract agreements. Despite the postponement, the company remains optimistic about future growth, with plans to pursue additional contracts and expand its joint drug discovery research. These efforts aim to enhance long-term business revenue and establish Veritas as a key player in mRNA-related drug discovery.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.